ArticleTranslational lung cancer research2026
A recurrence risk prediction model and recurrence patterns in pulmonary lymphoepithelial carcinoma based on clinical and dynamic hematologic parameters.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary lymphoepithelial carcinoma (pLELC) is a rare Epstein-Barr virus (EBV)-associated non-small cell lung cancer (NSCLC). In patients with resected pLELC, postoperative recurrence is the major barrier to long-term survival. However, predictors of recurrence remain unclear, and reliable risk prediction models are lacking. This study aimed to develop a recurrence risk prediction model for patients with resected pLELC based on clinical and dynamic hematologic parameters and to characterize postoperative recurrence patterns. Methods: We retrospectively analyzed patients who underwent radical resection for pLELC. Recurrence-related variables were screened by univariable and stepwise multivariable Cox regression to construct a predictive model. The model's performance was assessed via receiver operating characteristic (ROC) analysis, the concordance index (C-index), and bootstrap internal validation, with a comparison against the tumor-node-metastasis (TNM) staging system. Recurrence sites and their prognostic implications were also evaluated. Results: Of 238 patients, 57 developed recurrences. Independent predictors of recurrence were node (N) stage, central tumor location, elevated preoperative D-dimer, postoperative platelet count increase, and elevated postoperative neutrophil-to-lymphocyte ratio (NLR). The model demonstrated strong discriminative performance in the training cohort, with 1-, 3-, and 5-year of area under the curves (AUCs) of 0.822, 0.792, and 0.744, respectively, outperforming the conventional TNM staging system. Internal validation yielded a C-index of 0.752. Among patients with recurrence, the median disease-free survival (DFS) was 21.8 months. Most recurrences were locoregional (76.0%), and those with distant metastasis experienced significantly poorer post-recurrence survival (PRS) (P=0.04). Conclusions: Our recurrence prediction model for resected pLELC, which integrates clinical and dynamic hematologic factors, outperformed TNM staging. It provides a basis for stratifying postoperative surveillance and guiding early intervention in high-risk patients. Additionally, patients with distant metastasis had worse PRS than those with locoregional relapse, indicating distinct prognostic implications based on recurrence pattern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.